CLBT: Cellebrite Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
Cellebrite: 1-Year and 5-Year Forecast Outlook and Rating
Cellebrite (CLBT) has an immediate Strong Buy & Keep consensus AI recommendation, based on 11 AI analysts.
The 1-year target is $13.08 for , with +21.45% expected return (+21.45% including net dividends) and a STRONG BUY rating.
The 5-year target is $20.2 for , with +87.56% expected return (+87.56% including net dividends) and a STRONG BUY rating.
Latest available market price: USD 10.77, as of 20 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 25% (IL). One-off special payments are excluded.
Original published assumption: 0% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
Cellebrite Flagship Insight
The Cash Engine Must Prove Growth Beyond Its Fading Upgrade Cycle
High consensus supports resilient investigative subscriptions, but fading upgrade pricing shifts the burden to paid AI adoption and federal cloud deployments. Strong liquidity limits financing risk; purchased technology, equity dilution and unresolved acquisition clearance constrain shareholder economics. Durable renewals, not automatic index inclusion, determine valuation recovery.
How were the Investment Thesis and Forecasts created?
11 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Elon Musk (Visionary)
Warren Buffett (Value Purist)
Machiavelli (Insider)
J.P. Morgan (Titan)
Universal Investor (Polymath)
Ray Dalio (Strategist)
Michael Burry (Vulture)
Superintelligence (Anthropologist)
Sherlock Holmes (Whistleblower)
Ran across these frontier AI models
Google Gemini 4 Hydrogen
OpenAI GPT-6.1 Sol
Anthropic Claude Opus 5.5
Latest published deep-analysis batch. Audit published forecasts in full transparency
Cellebrite: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in Cellebrite at the latest market close (20 Nov 2026): $18,756 by Nov 2031 versus $14,502 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
Cellebrite's investment case is a growth handoff, not a frictionless rerating. Embedded forensic workflows and resilient renewals support recurring cash generation as Inseyets migration pricing fades. Selective Genesis adoption and federal cloud deployment can sustain low-teens expansion, with modest operating leverage rather than monopoly economics. Valuation remains sensitive to discount rates and the definition of distributable cash: recurring technology purchases sit outside reported free cash flow, while equity compensation dilutes ownership. The strongest counterargument is that these costs, acquisition restrictions and budget resistance already justify the discount. Public results known before the anchor support durability, not an undiscovered earnings surprise.
Key insights
- Judicial familiarity reduces replacement incentives, but continued access research is the admission fee; switching costs protect renewals without eliminating technological dependence.
- AI expands the paying audience beyond examiners, yet competes for existing agency budgets; usage must become incremental cash rather than defensive bundling.
- Regulatory clearance and domestic incorporation remove different barriers; liquidity funds the wait, but neither guarantees awards, index admission or successful capital allocation.
Continue reading Cellebrite analysis with Base subscription
See Base accessCellebrite: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 10.77, as of 20 Nov 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-11-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 25% (IL). One-off special payments are excluded.
Original published assumption: 0% per year.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 11 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 13 Nov 2026 at USD 11.53. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|---|---|---|---|
| $11.62 | +0.81% | +7.89% | +7.89% | Renewals and year-end cash collections support tentative improvement, but cautious guidance and unresolved Corellium ownership limit conviction. The weighted scenario favors modest stabilization rather than treating stronger cash generation as proof that migration-related deceleration has ended. | $10.97 | $12.32 | $736 | |
| $11.92 | +2.54% | +10.68% | +10.68% | Retention evidence, initial paid Genesis deployments and restructuring discipline begin rebuilding confidence. Redomiciliation progress helps sentiment, while competing scenarios retain spring procurement delays and cautious guidance, keeping the recovery dependent on operating evidence rather than approvals alone. | $10.63 | $12.94 | $724 | |
| $12.50 | +4.92% | +16.06% | +16.06% | Stable customer expansion and additional analytics deployments support a stronger recovery as corporate restructuring advances. Some paths anticipate procurement relief, while others retain Corellium restrictions; the synthesis rewards commercial progress without assuming automatic clearance or index admission. | $11.25 | $13.58 | $722 | |
| $13.08 | +4.58% | +21.45% | +21.45% | Modeled federal purchasing completions and international renewals improve visibility beyond the fading upgrade cycle. Genesis attachment and cost discipline support earnings expectations, although restrictive discount rates and lighter migration pricing keep the interpretation short of an unrestricted platform rerating. | $11.81 | $13.73 | $724 | |
| $13.62 | +4.17% | +26.46% | +26.46% | Annual renewal evidence and recurring revenue outgrowing central expenses support further appreciation. Cash conversion matters more than headline acceleration, with the stronger scenarios offset by continuing research costs, budget negotiations and the need to validate technology-adjusted economics. | $12.06 | $14.35 | $735 | |
| $13.85 | +1.68% | +28.60% | +28.60% | Broader investigator adoption and cloud collaboration begin offsetting mature extraction upgrades. The advance remains measured because several paths model a migration-related valuation reset, ownership overhang or procurement friction, rather than an uninterrupted improvement in customer spending. | $12.53 | $15.07 | $752 | |
| $14.12 | +1.92% | +31.10% | +31.10% | Departmental expansion and international cloud renewals support growth, but modeled budget delays and compatibility spending absorb part of the benefit. The balance favors gradual progress while preserving disagreement over whether new workflows replace migration uplift quickly enough. | $12.91 | $14.64 | $754 | |
| $14.81 | +4.90% | +37.51% | +37.51% | Agency renewals, international deployments and modeled release of delayed orders strengthen cash-flow visibility. Successful product updates support retention, while election-related procurement uncertainty remains a scenario risk rather than an assumed permanent impairment of investigative software demand. | $13.23 | $15.78 | $780 | |
| $15.31 | +3.41% | +42.15% | +42.15% | Multi-product renewals and subscription scale improve expected cash generation per share. Potential repurchases provide optional support, not an established commitment, while device-research cycles and agency transitions temper confidence in a smooth conversion of revenue growth into shareholder value. | $13.17 | $16.58 | $802 | |
| $15.52 | +1.38% | +44.10% | +44.10% | Deployment efficiency and broader analytics usage support incremental earnings, but competing offers and renewed technology spending restrain enthusiasm. The modeled gain reflects cash-backed execution, with capital returns conditional and research costs preventing a frictionless expansion in normalized margins. | $13.56 | $17.24 | $819 | |
| $15.59 | +0.41% | +44.75% | +44.75% | The advance nearly stalls as modeled procurement slowdowns and competitor bundling counter improving device coverage and geographic expansion. Disagreement is sharpest over whether technical adaptation restores earnings quickly or merely raises the cost of defending existing customer relationships. | $14.09 | $16.83 | $821 | |
| $16.36 | +4.95% | +51.90% | +51.90% | Renewal outcomes and resumed agency awards distinguish timing disruptions from franchise erosion. Wider Genesis attachment and controlled administration rebuild earnings confidence, while retained cash supports equity value without requiring either monopoly pricing or another substantial increase in valuation multiples. | $14.52 | $17.68 | $842 | |
| $16.91 | +3.39% | +57.01% | +57.01% | A broader recurring revenue base and disciplined staffing support continuing cash growth. Mature account penetration limits acceleration, and research-heavy scenarios temper margin gains; appreciation rests primarily on sustainable operating progress rather than assumed expiration of acquisition accounting charges. | $14.67 | $18.57 | $863 | |
| $17.14 | +1.35% | +59.15% | +59.15% | Workflow adoption and more repeatable deployments support modest progress despite competitive packaging and periodic security spending. Some paths anticipate easier discount rates, but the stronger common mechanism is improved customer economics without a proportionate expansion of central costs. | $15.04 | $19.14 | $871 | |
| $17.57 | +2.49% | +63.14% | +63.14% | International analytics adoption and cloud utilization offset mature extraction growth. The weighted balance remains positive, although several scenarios retain budget pauses and renewed access spending, emphasizing that deployment efficiency must translate into cash after technical maintenance. | $15.49 | $19.09 | $874 | |
| $18.26 | +3.94% | +69.55% | +69.55% | Multi-year renewals and modeled contract conversions reinforce the visibility of recurring earnings. A larger cash reserve supports financial resilience, while measured administrative leverage helps shareholder economics despite continuing research, compliance costs and increasingly mature top-line growth. | $15.80 | $19.86 | $896 | |
| $18.85 | +3.24% | +75.02% | +75.02% | Annual results in the modeled scenario show a larger recurring earnings base and improving cash conversion after technology purchases. Controlled dilution and possible capital returns support per-share progress, while competitive pressure prevents an unqualified premium for mature software revenue. | $16.03 | $20.9 | $912 | |
| $19.05 | +1.10% | +76.88% | +76.88% | Cloud attachment and workflow consolidation sustain operating growth, but investors increasingly discount a slower terminal expansion rate. Conditional repurchases and retained liquidity provide support, leaving appreciation restrained by valuation sensitivity rather than a deterioration in the core renewal franchise. | $16.44 | $21.5 | $924 | |
| $19.46 | +2.14% | +80.69% | +80.69% | Durable subscriptions and wider workflow usage maintain earnings expectations as the platform matures. Ongoing research, competitive bidding and compliance prevent margin overshoot, so positive shareholder progress depends on disciplined reinvestment rather than assuming access leadership becomes maintenance-free. | $16.61 | $21.2 | $939 | |
| $20.2 | +3.91% | +87.56% | +87.56% | Renewals and recurring cash generation support the modeled terminal business economics. The endpoint reflects a successful but measured growth handoff, preserving discounts for dilution, technical dependence and regulatory constraints rather than capitalizing an exceptional AI outcome. | $16.95 | $22.1 | $965 |
Show remaining 18 quartersCollapse to first 2 quarters
All 20 quarters are displayed in the table above.
Cellebrite Stock Analysis & Scenarios Deep Dive
Cellebrite: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Coverage of the August guidance reset and November revenue trim depicts an execution-challenged grower whose upgrade boost is fading. Some cited analyst commentary remains constructive, so the inputs do not establish uniform bearish positioning. Low-growth assumptions are inferred from valuation, not directly measured; company results and media reactions should not be confused with a verified expectations survey.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd modestly underestimates value, although the directional gap is conditional rather than demonstrated by positioning data. Recurring expansion can outlast migration repricing because agencies buy continuing evidence access, not just upgrades. That supports an earnings-led recovery rather than an AI-driven multiple leap. The strongest challenge is economic cash yield: technology purchases, dilution and restricted Corellium integration absorb part of the apparent discount. November results were already public at the anchor, making durability interpretation—not informational novelty—the potential edge.
Repricing Catalyst
What could make the market recognize and close that gap? Two successive 2027 updates showing resilient retention and paid Genesis expansion would provide the clearest trigger, because they separate recurring demand from exhausted migration pricing. February-May disclosures are the first test. Targeted first-half redomiciliation and a commercially useful Corellium agreement could reinforce an earnings-led recovery during 2027-2028, but approvals, funded awards and index admission remain separate hurdles. Larger agency mandates offer a further 2027-2029 catalyst, not a prerequisite.
Cellebrite: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Fear
- Volatility Regime
- High Erratic
- Convergence Cycle Position
- Stabilization
The reports predominantly describe cautious stabilization with substantial volatility, not renewed momentum. The decisive tension is whether stronger cash generation restores confidence before upgrade exhaustion becomes visible. A minority expects smoother compounding, but execution evidence remains necessary for durable recognition.
Macro Regime Fit
Does the current market environment support the thesis? The supplied regime is mixed, with a valuation headwind. Elevated sovereign yields compete with cash-flow yields and constrain agency purchasing power, while investigative workloads support comparatively resilient demand. Minimal financial borrowing limits refinancing exposure, making discount rates and procurement timing more consequential than financing costs. Disinflation would help; fiscal restraint or regional disruption would hinder execution.
Advisor Disagreement
What do our AI Advisors disagree about most? The substantive debate is whether recurring workflows and new products support a modest discount or whether compensation, technical maintenance and slower upgrades already justify near-fair valuation. More optimistic cases assume broader platform adoption and stronger cash conversion; cautious cases require continued research without equivalent pricing gains. Another disagreement concerns whether redomiciliation materially improves sales before national-security restrictions are settled. Smaller cash balances and weaker trailing profits often reflect narrower definitions or earlier endpoints, not conflicting economics. Stable retention plus improving cash flow after technology purchases would resolve more than another adjusted-margin beat.
Thesis Change
What changed in the thesis since the previous forecast? Durable investigative demand still anchors the thesis, but structural upgrade deceleration and acquisition restrictions materially narrow the earlier recovery argument. -- The prior view treated procurement slippage chiefly as deferred revenue. Current evidence adds fading Inseyets pricing uplift and actual Corellium churn, requiring new paid workflows rather than administrative normalization alone. -- Redomiciliation no longer carries an automatic clearance or index-inclusion assumption. Unresolved acquisition restrictions and purchased technology excluded from reported free cash flow make recognition more conditional, while liquidity and renewals preserve the core franchise premise.
Cellebrite: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Evidence workflows anchor renewals | Competitive Positioning | +45% | +60% | Embedded investigative processes make replacement costly, not impossible. Examiner training, evidentiary continuity and established agency workflows support recurring renewals and account expansion, consistent with reported retention. These advantages should persist across procurement cycles, sustaining earnings visibility, but depend on continued technical usefulness rather than an exclusive legal entitlement to courtroom evidence. |
| AI expands agency wallets | Innovation And Product | +30% | +40% | Genesis and collaboration tools can extend spending beyond specialist examiners to investigators facing evidence backlogs. Initial paid adoption supports incremental monetization over five years, spreading distribution costs across more users. The base case assumes selective account expansion, not platform dominance; competing bundles and fixed agency budgets limit how much usage becomes genuinely additional revenue. |
| Subscription scale releases cash | Operational Efficiency | +25% | +35% | A larger recurring revenue base can outgrow central administration and distribution costs, supporting gradual operating leverage. Recent profitability demonstrates that potential without establishing a permanently exceptional quarterly margin. Physical capital needs remain modest, but research, purchased technology and hosting still consume cash, so shareholder gains should trail frictionless software extrapolations. |
| Federal cloud widens eligibility | Regulatory | +25% | +30% | Documented high-security cloud authorization expands the pool of eligible federal deployments and supports longer-duration collaboration contracts. Over five years, incremental procurement should deepen account penetration and recurring earnings. Certification removes a prerequisite rather than guaranteeing awards; appropriations, ownership reviews and implementation requirements remain distinct obstacles between technical eligibility and recognized revenue. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (at least 75% probability of occurrence, as generation guidance). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Migration pricing loses momentum | Competitive Positioning | -18% | -18% | With most eligible customers already migrated to Inseyets, the strongest conversion-related pricing uplift is finite. Management expects lighter expansion from remaining accounts. This creates a persistent growth-comparison burden and shifts sales toward harder-won incremental workflows, moderating earnings momentum and valuation support unless new modules replace the exhausted migration contribution. |
| Access demands continual reinvestment | Innovation And Product | -15% | -20% | Device access is a moving technical advantage that must be renewed through research, compatibility work and purchased capabilities. This recurring burden absorbs gross profit even when access remains competitive. Research already reduces operating cash flow; purchased intangibles require separate scrutiny, preventing low physical capex from being mistaken for negligible economic reinvestment. |
| Equity awards dilute participation | Capital Allocation | -12% | -15% | Recurring compensation expense and share issuance separate enterprise cash growth from existing shareholders' participation. Without an established offsetting repurchase program, per-share progress can lag operating expansion. Compensation affects earnings, while dilution itself changes ownership rather than aggregate profit; valuation should recognize both without charging twice for the same economic transfer. |
| Procurement permission slows conversion | Regulatory | -10% | -10% | Agency approvals, ownership reviews, export screening and compliance obligations make investigative demand slower to monetize than ordinary software usage. Corellium's constrained operations illustrate the distinction between customer interest and permissible deployment. These recurring requirements raise selling costs and delay earnings, even without a sweeping prohibition or an adverse final acquisition ruling. |
Cellebrite: What Could Break or Accelerate the Thesis
Event Risk Score: Moderate 57/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Device redesign blocks useful access | 25% | -45% | A major mobile-security redesign during 2027-2030 could block economically important device cohorts for several renewal cycles. Persistent coverage gaps accompanied by customer migration—not an ordinary patch delay—would identify the event. Revenue and pricing would weaken while remediation costs rose. Probability remains limited by research depth and historical adaptation; current architecture documentation does not establish an inevitable defeat. |
| CFIUS orders Corellium separation | 40% | -25% | A binding 2027-2028 divestment order, or restrictions that destroy commercially useful integration, would impair the acquisition thesis. Disposal losses, reduced research synergies and weakened acquisition credibility could lower both earnings expectations and valuation. Probability remains below a majority because negotiated mitigation is possible, and the supplied disclosures establish unresolved review rather than a final adverse decision. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Genesis wins an agency standard | 40% | +40% | A funded multi-agency Genesis mandate during 2027-2029 would establish repeatable commercial value beyond pilots and isolated add-ons. Demonstrable expansion economics could accelerate adoption across existing agencies, lifting earnings and the valuation assigned to platform revenue. Probability remains limited because budgets, evidentiary validation and paid deployment commitments must align; product availability alone establishes none of them. |
| Domestic clearance unlocks restricted demand | 45% | +25% | A commercially useful Corellium agreement, completed U.S. redomiciliation and a subsequent material government award during 2027-2028 could remove a specific ownership discount. Reduced sales restrictions would improve acquisition payback and recurring earnings visibility. Probability remains limited because national-security approval, corporate restructuring and customer purchasing are separate hurdles; index admission would be additional optionality, not an automatic consequence. |
Company Financial AnalysisCellebrite: Earnings and Financials Analysis by AI
Financial figures available as of Nov 16, 2026. Only filings and source records available by this analysis date are included. View latest Cellebrite financials here.
Earnings and financials
According to the company's November Q3 2026 release, quarterly revenue reached $149 million and trailing free cash flow reached $166 million. Federal and international business supported a recovery after a weaker first half. This strengthens the operating picture, but does not erase cautious guidance or prove that growth is accelerating permanently. Historical SPAC-related accounting losses were not equivalent to operating cash losses. Today's differences between earnings and cash deserve closer attention: employee equity awards, acquisition amortization and subscription collection timing all matter. Year-to-date reported earnings still lagged the prior year, so the clearest interpretation is improving operations with uneven shareholder economics—not an uninterrupted profit surge.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 475.7M | USD 78.3M | USD 155.7M |
| 2024 | USD 401.2M | USD -283M | USD 121.6M |
| 2023 | USD 325.1M | USD -81.1M | USD 94.1M |
| 2022 | USD 270.7M | USD 120.8M | USD 11.5M |
| 2021 | USD 246.2M | USD 71.4M | USD 27.9M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 57.9x | TTM | Native | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | 7.0x | Annual | Native | USD / USD |
| 2021 | 22.4x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company's Q3 2026 tables report an 81.2% GAAP gross margin versus an 85.7% adjusted gross margin. Acquisition amortization explains much of that difference, so the lower reported figure alone does not prove weaker product pricing. Operating profitability also recovered from the research-heavy first half, contrary to an interpretation of uninterrupted margin deterioration. There is genuine potential to spread administration and selling costs across more subscription revenue. However, employee equity awards, cloud hosting, AI processing and continual access research remain economic costs. Adjusted profitability therefore cannot be treated as fully available shareholder cash. The investment case requires improving cash generation per share alongside reported earnings, not simply wider exclusions from adjusted results.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 66.5M | 14.0% | 16.5% |
| 2024 | USD 56.9M | 14.2% | -70.5% |
| 2023 | USD 33.2M | 10.2% | -24.9% |
| 2022 | USD 1M | 0.4% | 44.6% |
| 2021 | USD 13.8M | 5.6% | 29.0% |
Balance sheet and leverage
The company's September 2026 disclosures show approximately $593 million in cash, deposits and marketable securities, with no conventional financial borrowings listed. Approximately $23 million of lease obligations remains. Smaller cash-only and current-security subtotals use narrower definitions; they should not be mistaken for the value of the entire investment portfolio. This liquidity lets Cellebrite fund research and withstand delayed government payments without depending on new lenders. It is not all freely distributable surplus: prepaid subscriptions require future service, acquisitions carry contingent commitments, and restructuring or regulatory mitigation may consume resources. Most importantly, money cannot resolve ownership restrictions by itself. Financial resilience protects operating flexibility, not the economic success of every acquisition.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 22.7M | USD 437.1M | USD 101.8M net cash | USD -414.4M | 1.56x |
| 2024 | USD 11M | USD 447.2M | USD 180.7M net cash | USD -436.3M | 1.92x |
| 2023 | USD 14.1M | USD 302.9M | USD 175.4M net cash | USD -288.8M | 1.66x |
| 2022 | USD 15.4M | USD 183.6M | USD 72.3M net cash | USD -168.3M | 1.42x |
| 2021 | USD -146M | USD 181.6M | USD 146M net cash | USD -327.5M | 1.46x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company's September 2026 year-to-date cash-flow tables show $24 million of purchased intangibles alongside $11 million of physical capital spending. Its free-cash-flow definition deducts the equipment spending but excludes those technology purchases. That makes the familiar low-capex software description incomplete: maintaining valuable access capabilities can require cash beyond computers and offices. Research spending is another major investment, but it already reduces operating cash flow and should not be deducted twice. Acquisitions are separate commitments whose payback remains uncertain, particularly under Corellium's restrictions. Some normalization for technology purchases is warranted; assuming every purchase repeats unchanged would also overstate what the evidence establishes.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 13.2M | USD 113.9M |
| 2024 | USD 10.6M | USD 98.4M |
| 2023 | USD 7.9M | USD 84.4M |
| 2022 | USD 9.1M | USD 80.6M |
| 2021 | USD 8.1M | USD 65.5M |
Behind the synthesisCellebrite: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 11 advisor opinions. The weights and rationales below are retained from that synthesis.
Reported retention, subscription mix and cash generation support a durable investigative franchise, while management commentary supports fading migration-related pricing. These observations have stronger foundations than claims of monopoly rents or guaranteed institutional inflows. Much apparent agreement traces to the same earnings release and transcripts, so repetition receives no independent evidentiary credit. Greater weight goes to source-linked analyses that distinguish operating recovery from accounting effects, purchased technology from physical capex, and procurement eligibility from actual awards. The strongest countercase is that compensation, technical renewal costs and acquisition restrictions already justify much of the valuation discount. Unsupported dilution extrapolations, automatic index inclusion and precise political outcomes receive less influence. Smaller liquidity figures often reflect narrower asset definitions rather than economic disagreement. November results were public before the anchor; they improve the analytical baseline but do not constitute an undiscovered catalyst. Remaining uncertainty concerns paid platform adoption and commercially useful regulatory clearance.
Individual targets retain their original dates. Returns and ratings use the same latest available market close and dividend assumptions as the Consensus.
All 11 opinions
Consensus weight Allocation: 18.0/100. Weight Allocation Rationale: The highest weight reflects a material, source-linked distinction: purchased intangibles sit outside reported free cash flow. Separating operating cash generation, interest income, retained cash and projected dilution improves valuation consistency. The weight is not dominant because recurring technology-purchase normalization, terminal cash retention and the growth handoff remain judgmental.
The 1-year target is $13.31 for , with +23.54% expected return and a STRONG BUY rating. The 5-year target is $22.1 for , with +105.25% expected return and a STRONG BUY rating.
Consensus weight Allocation: 15.0/100. Weight Allocation Rationale: Primary filings, company tables, platform-security documentation and competitor evidence support a balanced distinction between embedded workflows and technological dependence. Regulatory clearance is appropriately conditional, and valuation avoids separately adding cash to equity cash flow. Remaining limitations include uncertain technology-purchase normalization and an unverified premium terminal capitalization.
The 1-year target is $13.04 for , with +21.12% expected return and a STRONG BUY rating. The 5-year target is $21.4 for , with +99.09% expected return and a STRONG BUY rating.
Consensus weight Allocation: 15.0/100. Weight Allocation Rationale: Official certification evidence and filings substantiate procurement eligibility, recurring demand and financial resilience without claiming monopoly control. The separation of corporate domicile from commercially useful clearance is particularly persuasive. Weight remains bounded because terminal cash conversion and quarterly procurement recoveries are scenarios, and underlying company disclosures overlap with other reports.
The 1-year target is $13.56 for , with +25.86% expected return and a STRONG BUY rating. The 5-year target is $22.1 for , with +105.16% expected return and a STRONG BUY rating.
Consensus weight Allocation: 11.0/100. Weight Allocation Rationale: The report connects reported retention, federal recovery and fading migration benefits to a restrained growth scenario, supported by identifiable filings and transcripts. Its distinction between enterprise progress and shareholder dilution is useful. Narrow liquidity definitions, speculative political outcomes and assumed future repurchases limit the weight.
The 1-year target is $13.06 for , with +21.23% expected return and a STRONG BUY rating. The 5-year target is $17.79 for , with +65.18% expected return and a BUY rating.
Consensus weight Allocation: 10.0/100. Weight Allocation Rationale: The strongest distinctive contribution is the challenge to headline cash-flow cheapness through compensation costs and acquisition risk. That counterargument survives scrutiny and tempers rerating expectations. However, buybacks, ownership-overhang resolution and some regulatory outcomes are assumed rather than established, while liquidity and acquisition figures use narrower or differing definitions.
The 1-year target is $11.83 for , with +9.80% expected return and a BUY rating. The 5-year target is $17.52 for , with +62.64% expected return and a BUY rating.
Consensus weight Allocation: 7.0/100. Weight Allocation Rationale: The cash-generation and upgrade-saturation arguments are economically coherent and consistent with reported operating evidence. Weight is limited because redomiciliation, regulatory clearance, index demand and repurchases are linked too automatically. Several sources repeat company disclosures, while dilution estimates and terminal valuation definitions require qualification.
The 1-year target is $13.20 for , with +22.59% expected return and a STRONG BUY rating. The 5-year target is $19.26 for , with +78.85% expected return and a BUY rating.
Consensus weight Allocation: 5.5/100. Weight Allocation Rationale: The report sensibly adjusts cash economics for compensation and recognizes fading upgrade uplift alongside durable subscriptions. Its evidence substantially overlaps with the shared earnings release. Strong claims about automatic procurement relief, index admission, activist pressure and large repurchases exceed the supplied support, limiting its relative contribution.
The 1-year target is $13.48 for , with +25.16% expected return and a STRONG BUY rating. The 5-year target is $20.7 for , with +92.51% expected return and a STRONG BUY rating.
Consensus weight Allocation: 5.5/100. Weight Allocation Rationale: Compensation reconciliation, deferred-revenue interpretation and explicit Corellium downside support its cautious cash-durability thesis. The relative weight is constrained by inconsistent valuation labels, automatic index assumptions and reliance on repeated earnings commentary rather than independent confirmation. Its skepticism toward adjusted profitability remains useful despite those limitations.
The 1-year target is $12.57 for , with +16.70% expected return and a STRONG BUY rating. The 5-year target is $18.39 for , with +70.74% expected return and a BUY rating.
Consensus weight Allocation: 4.5/100. Weight Allocation Rationale: The report usefully emphasizes certification, ownership structure and acquisition approval as commercial variables. Its relative weight is lower because political access is sometimes treated as durable competitive exclusion, index inflows appear automatic, and lease obligations are inconsistently labeled as debt. These weaknesses do not invalidate its supported regulatory insights.
The 1-year target is $13.74 for , with +27.57% expected return and a STRONG BUY rating. The 5-year target is $18.60 for , with +72.68% expected return and a BUY rating.
Consensus weight Allocation: 4.5/100. Weight Allocation Rationale: The connection between evidence access, AI workflows and agency labor budgets is useful, as is recognition of persistent technical reinvestment. Weight is restrained by unsupported physical-limit language, monopoly claims and automatic index assumptions. Substantial terminal cash accumulation also depends on capital-allocation choices that are not established.
The 1-year target is $13.07 for , with +21.31% expected return and a STRONG BUY rating. The 5-year target is $19.72 for , with +83.06% expected return and a BUY rating.
Consensus weight Allocation: 4.0/100. Weight Allocation Rationale: The fair-value countercase correctly treats continuing research as an economic necessity and challenges effortless operating leverage. Its lower weight reflects missing source receipts and reliance on an earlier financial endpoint that materially understates the supplied cash-generation baseline, not preparation timing. Its unusually smooth path also underrepresents identified execution risks.
The 1-year target is $11.99 for , with +11.33% expected return and a BUY rating. The 5-year target is $16.95 for , with +57.34% expected return and a BUY rating.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v9 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this Cellebrite forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Sources retained from AI Researcher searches
Asset-specific · Researcher web40 available sources from this batch (104 recorded). The first 15 are shown below; expand to read the rest.
Some model providers retained only the consulted domain, not an exact article URL. Those domains are shown as evidence without inventing a link.
- sec.gov sec.gov
- www.sec.gov sec.gov
- Cellebrite Government Cloud (CGC) | FedRAMP Marketplace fedramp.gov
- cele-20251231 sec.gov
- cele-20251231 sec.gov
- Cellebrite DI Ltd. - Form 6-K - FY2026 sec.gov
- https://www.sec.gov/Archives/edgar/data/1854587/000121390026091208/ea030247001ex99-1.htm?utm_source=openai sec.gov
- https://www.sec.gov/Archives/edgar/data/1854587/000121390026118368/ea031199501ex99-1.htm?utm_source=openai sec.gov
- www.sec.gov sec.gov
- cellebrite.com cellebrite.com
- investing.com investing.com
- prnewswire.com prnewswire.com
- seekingalpha.com seekingalpha.com
- stocktitan.net stocktitan.net
- finviz.com finviz.com
Show 25 more sources
- fool.com fool.com
- biggo.com biggo.com
- calcalistech.com calcalistech.com
- tradingview.com tradingview.com
- mlq.ai mlq.ai
- substack.com substack.com
- perplexity.ai perplexity.ai
- youtube.com youtube.com
- finsee.ai finsee.ai
- forensicfocus.com forensicfocus.com
- Cellebrite PPT Template investors.cellebrite.com
- CLBT Q3'26 Historical Financial Tables and Supplemental Data.xlsx investors.cellebrite.com
- koalagains.com koalagains.com
- marketbeat.com marketbeat.com
- myallies.com myallies.com
- note.com note.com
- quartr.com quartr.com
- reddit.com reddit.com
- stockanalysis.com stockanalysis.com
- tickertrends.io tickertrends.io
- tipranks.com tipranks.com
- advfn.com advfn.com
- aktien.guide aktien.guide
- blockleviton.com blockleviton.com
- Why is Cellebrite stock plunging today? By Investing.com ca.investing.com
64 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2026 Year-to-Date Global Market and World-Events Context Through November 14
Download Archived SnapshotCoverage 2026-01-01 to 2026-11-14 · Knowledge cutoff 2026-11-14
January 1-November 14, 2026: persistent inflation, partial oil supply recovery, US midterms and trade, AI financing, and uneven growth.
Archived context covering 2026-01-01 to 2026-11-14. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 96K bytes
- Words
- 14.2K words
- Characters
- 96K characters
- Est. tokens (characters ÷ 4)
- 24K tokens
Fed held at 3.75%-4.00%; Democrats won the next Congress, Nvidia changed leadership and Anthropic filed preliminary IPO terms. Markets through November 13.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| US tariff reset, trade truce and incoming divided government | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2019-12-31–2025-12-31, 7 periods; Quarterly fiscal periods: 2023-12-31–2026-06-30, 11 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
11 fieldscash · commonStockSharesOutstanding · netDebt · netReceivables · +7 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.
Cellebrite: forecast questions
What is Cellebrite (CLBT)'s 1-year price forecast?
Cellebrite's 1-year target is $13.08 for Nov 2027. The current AI rating is STRONG BUY. The expected return from the recorded close is +21.45%, or +21.45% modeled return including net dividends. Latest available market price: USD 10.77, as of 20 Nov 2026. The target date is fixed at publication.
What is Cellebrite (CLBT)'s 5-year price forecast?
Cellebrite's 5-year target is $20.2 for Nov 2031. The current AI rating is STRONG BUY. The expected return from the recorded close is +87.56%, or +87.56% modeled return including net dividends. Latest available market price: USD 10.77, as of 20 Nov 2026. The target date is fixed at publication.
How can I compare the AI opinions and audit past Cellebrite forecasts?
11 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History lists the available batches with their original publication dates.
How does an AI-generated forecast for Cellebrite differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for Cellebrite is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
If iPulse AI produces thousands of investment reports - work estimated to require over 100,000 traditional analyst hours - isn't that just "AI slop" at scale?
No. iPulse AI produces AI-generated research at scale, but the purpose is depth of analysis, comparison, and accountability. The number of reports is a consequence of the research process; it is not the goal.
iPulse AI does not produce thin copies of existing websites, articles, or investment reports. We use frontier models as an Analytical Intelligence layer. Our Financial Experts select, validate, curate, and supply the input data, including proprietary inputs, so the models work from a prepared evidence base.
In Researcher mode, models can also search the web to check current information, test assumptions, and investigate evidence that may be missing from the supplied data. This can include lobbying expenditure, management developments, regulatory decisions, or other facts relevant to a particular investment thesis. Thinker mode focuses on deep reasoning over the supplied data and context.
Our process goes much further than asking ChatGPT to evaluate a stock. Our team designs structured investment frameworks inspired by the approaches of influential investors, economists, political thinkers, and technological visionaries. These are AI analytical frameworks, not reports written or endorsed by the people who inspired them.
Each asset is analyzed separately through multiple frameworks and configurations, using specialized inputs and task instructions. Different perspectives examine different questions: valuation, business quality, technological disruption, macroeconomic conditions, political influence, financial risks, and more.
Cloud infrastructure allows these workflows to run at scale. That scale also comes with quality assurance at scale: up to 30% of report-generation attempts fail our QA checks. We rerun failed attempts until a clean report passes those checks. Users are presented only with reports that have passed QA.
This explains the volume. The value comes from what we do with the analysis.
A second layer synthesizes the individual reports into an asset-level consensus. This is where we recommend starting when researching a particular asset: it brings together the central thesis, supporting evidence, risks, and disagreements while preserving access to the underlying opinions.
We then compare assets through our proprietary iPulse AI Consensus Score, whose methodology is publicly explained. This helps users move from understanding one asset to comparing opportunities across the analyzed universe.
A further research and editorial layer examines leading candidates, checks current evidence, and develops focused Editorial Top Picks across broad-market and dedicated asset categories. Human editors review the evidence and approve each published edition. For example, explore our Best Long-Term Investments.
But the process does not end when a report is published. We preserve past forecasts so users with the relevant subscription can inspect what the system actually said and compare it with subsequent market outcomes. As more forecasts reach their target dates, the historical record becomes more useful for evaluating which approaches worked, which failed, and under what conditions.
We publish research on our website, arXiv, and Zenodo, alongside explanatory writing on Medium. We use the evidence to refine our data, frameworks, validation, and workflows, and document important findings in Lessons Learned.
The standard we ask users to judge us by is the reasoning, evidence, and historical record behind the research.
How does the iPulse AI Engine work?
The engine runs AI advisor configurations against a shared set of research inputs. The engine history explains the research workflow and what changed between versions.








